C3 to sell CellSpray after review

PERTH-BASED burns treatment developer Clinical Cell Culture Ltd, or C3, last week announced it would close its American offices and sell its CellSpray technology after completing a strategic review of its options. C3 chief executive Bob Atwill will resign from the board after 10 months in the role, to be replaced by chief financial officer Andrew Cannon, who will also retain his financial responsibilities.

Add your comment

BNIQ sponsored byECU School of Business and Law


6th-Australian Institute of Management WA20,000
7th-Murdoch University16,584
8th-South Regional TAFE10,549
9th-Central Regional TAFE10,000
10th-The University of Notre Dame Australia6,708
47 tertiary education & training providers ranked by total number of students in WA

Number of Employees

BNiQ Disclaimer